Business Context and Reporting Period
Company: Lifecore Biomedical, Inc. (LFCR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2025
Business Overview: A fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and hyaluronic acid (HA) manufacturing.
Fiscal Year Change: The Company changed its fiscal year-end from the last Sunday of May to December 31, effective May 26, 2025. This report compares the quarter ended September 30, 2025, to the three months ended August 25, 2024.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 (Ended Sep 30) | Prior Period (Ended Aug 25, 2024) |
|---|---|---|
| Total Revenues | $31,109 | $24,705 |
| Gross Profit | $7,791 | $5,387 |
| Gross Margin | 25.0% | 21.8% |
| Operating Loss | $(3,067) | $(11,584) |
| Net Loss | $(9,991) | $(16,230) |
| Loss Per Share (Basic & Diluted) | $(0.29) | $(0.53) |
| Cash and Cash Equivalents | $18,856 | $8,265 (May 25, 2025) |
| Net Cash Provided by Operating Activities | $1,762 | $(613) |
| Total Debt (Principal) | $191,468 | $188,350 |
| Debt Derivative Liability | $25,491 | $24,991 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 26% ($6.4 million). HA manufacturing revenue surged 107% ($4.8 million) due to increased customer demand, while CDMO revenue grew 8% ($1.6 million) driven by higher sales volumes.
- Profitability Improvement: Operating loss narrowed significantly by $8.5 million (74% reduction) primarily due to a $5.9 million decrease in Selling, General, and Administrative (SG&A) expenses. SG&A declined due to reduced non-recurring legal and audit fees related to legacy matters.
- Cash Flow Turnaround: Operating cash flow improved by $2.4 million, shifting from a use of cash to a generation of cash, driven by improved earnings adjusted for non-cash items and working capital management.
- Interest Expense: Net interest expense increased by $1.0 million, largely due to the accumulation of interest paid-in-kind (PIK) on the related-party term loan with Alcon.
Outlook, Risks, and Management Commentary
- Operational Efficiency: Management reports a >20% improvement in workforce productivity over the past year. A new ERP system is expected to go live in Q1 2026 to further reduce costs and improve inventory control.
- Liquidity Position: The Company holds $18.9 million in cash and has approximately $23.6 million available under its Revolving Credit Facility. Management believes current resources are sufficient for the next 12 months.
- Debt Obligations: The Company has significant related-party debt with Alcon ($179.6 million principal) bearing an effective annual interest rate of 20.9% (including PIK and amortization). The Term Loan matures in May 2029.
- Preferred Stock: Series A Redeemable Convertible Preferred Stock has a liquidation preference of $47.5 million. Holders are entitled to 7.5% annual dividends payable in-kind. Redemption rights may be exercised after June 29, 2026.
- Legal Proceedings:
- Investor Dispute: A lawsuit by 22NW Fund regarding misrepresentations and registration delay fees is ongoing; the Company intends to vigorously defend.
- Class Action: A proposed settlement regarding a securities class action was reached in principle in November 2025, expected to be covered by insurance with no material loss to the Company.
- SEC Subpoena: The Company is cooperating with an SEC investigation regarding a prior financial statement restatement.
- Internal Controls: Disclosure controls and procedures were deemed ineffective as of September 30, 2025, due to material weaknesses in internal control over financial reporting. Remediation efforts are ongoing, including the planned ERP implementation.
Investor Verification Checklist
- Debt Sustainability: Verify the Company's ability to service the $179.6 million related-party term loan with a 20.9% effective interest rate and the potential cash outflow required for Preferred Stock redemption post-June 2026.
- Customer Concentration: Confirm the stability of revenue from Alcon, which accounted for 38% of total revenue in Q1 2025.
- Internal Control Remediation: Monitor progress on the remediation of material weaknesses in internal controls, specifically the timeline and success of the Q1 2026 ERP implementation.
- Litigation Outcomes: Track the final court approval of the class action settlement and the resolution of the 22NW Fund investor dispute.
- Working Capital: Assess the sustainability of the recent improvement in operating cash flow given the high level of non-cash interest expense.